Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis

被引:5
|
作者
Bai, Yuping [1 ]
He, Tingting [1 ]
Zhang, Liyan [2 ]
Liu, Qianqian [1 ]
Yang, Jing [1 ]
Zhao, Ziru [1 ]
Yang, Kehu [3 ]
Zhang, Min [4 ]
机构
[1] Gansu Univ Chinese Med, Sch Basic Med, Lanzhou, Peoples R China
[2] Hebei Cangzhou Hosp Integrated Tradit Chinese & W, Dept Pathol, Cangzhou, Peoples R China
[3] Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China
[4] Gansu Prov Hosp, Dept Pathol, Lanzhou, Peoples R China
来源
BMJ OPEN | 2022年 / 12卷 / 09期
基金
中国国家自然科学基金;
关键词
lymphoma; immunology; haematology; PREDICTS POOR-PROGNOSIS; TUMOR MICROENVIRONMENT; EXPRESSION; RITUXIMAB; CYCLOPHOSPHAMIDE; VINCRISTINE; IMPACT;
D O I
10.1136/bmjopen-2021-060659
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We aimed to comprehensively evaluate the relationship between forkhead box P3 (FOXP3(+)) regulatory T cell (Treg) expression and diffuse large B-cell lymphoma (DLBCL) prognosis and to explore the sources of heterogeneity of the results. Design Systematic review and meta-analysis. Data sources We searched the Cochrane Library, PubMed, Embase and Web of Science databases up to 5 December 2021. Eligibility criteria We included studies that analysed the prognostic significance of FOXP3(+) Tregs in DLBCL. We included studies reported in Chinese or English that reported HRs and related 95% CIs for prognosis. Data extraction and synthesis We extracted data from eligible studies. HRs and 95% CIs were used to assess the prognostic value. Results Fourteen eligible studies were identified. FOXP3(+) Treg expression was not associated with overall survival (OS) (HR=0.72, 95% CI 0.45 to 1.16) or progression-free survival (HR=0.86, 95% CI 0.54 to 1.38). The three approaches used to measure FOXP3(+) Treg expression (p(interaction)<0.001) may be the source of the heterogeneity of the results. Subgroup analysis found that a higher expression of FOXP3(+) Tregs was associated with better OS in all populations and in Asians when FOXP3(+) Treg expression was measured by the number of positive cells (HR=0.36 (95% CI 0.22 to 0.58) in the former, HR=0.33 (95% CI 0.20 to 0.55) in the latter) or the percentage of positive cells (HR=0.49 (95% CI 0.27 to 0.89) in the former, HR=0.38 (95% CI 0.21 to 0.70) in the latter). However, when measured by the score, inverse results were found (HR=1.56, 95% CI 1.01 to 2.42). Conclusions Approaches to measuring FOXP3(+) Treg expression might be the major source of heterogeneity in studies of the prognostic significance of FOXP3(+) Tregs in DLBCL. FOXP3(+) Treg expression might be used to predict the prognosis of patients with DLBCL when FOXP3(+) Treg expression is calculated by the number or the percentage of positive cells, especially in Asian populations.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Prevalence of FoxP3+ Cells Does Not Correlate With Ki67 Expression in Canine Diffuse Large B-cell Lymphoma
    Muir, C. F.
    Priestnall, S. L.
    Hibbert, A.
    Brown, C.
    Garden, O. A.
    Scase, T.
    JOURNAL OF COMPARATIVE PATHOLOGY, 2017, 157 (01) : 15 - 22
  • [22] The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
    Hwang, Jisun
    Suh, Chonghyun
    Kim, Kyungwon
    Kim, Hosung
    Kim, Austin I.
    Craig, Jeffrey W.
    Chen, Ke Xun
    Roberson, Joel
    Guenette, Jeffrey P.
    Huang, Raymond Y.
    CANCERS, 2021, 13 (13)
  • [23] Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma
    Petronilho, Sara
    Sequeira, Jose Pedro
    Paulino, Sofia
    Lopes, Paula
    Lisboa, Susana
    Chacim, Sergio
    Lobo, Joao
    Teixeira, Manuel
    Jeronimo, Carmen
    Henrique, Rui
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):
  • [24] Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis
    Meng, Fanlu
    Zhong, Diansheng
    Zhang, Linlin
    Shao, Yi
    Ma, Qing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (10): : 17515 - 17522
  • [25] A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma
    Fang, Cheng
    Xu, Wei
    Li, Jian-Yong
    ANNALS OF HEMATOLOGY, 2010, 89 (11) : 1107 - 1113
  • [26] Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients
    Liu, Fangfang
    Li, Yaqing
    Ren, Meijing
    Zhang, Xinmin
    Guo, Xiaojing
    Lang, Ronggang
    Gu, Feng
    Fu, Li
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (02) : 459 - 467
  • [27] Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
    Tzankov, Alexandar
    Meier, Cecile
    Hirschmann, Petra
    Went, Philip
    Pileri, Stefano A.
    Dirnhofer, Stephan
    HAEMATOLOGICA, 2008, 93 (02) : 193 - 200
  • [28] Influence of Statins on the Survival Outcomes of Patients with Diffuse Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
    Li, Yanbing
    Zhou, Huijie
    Zou, Liqun
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2022, 2022
  • [29] The Prognostic Value of Blood-Based Biomarkers in Patients With Testicular Diffuse Large B-Cell Lymphoma
    Yang, Jing
    Guo, Xinli
    Hao, Jianqi
    Dong, Yiting
    Zhang, Tao
    Ma, Xuelei
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [30] Prognostic value of tumor-infiltrating Foxp3+regulatory T cells in patients with breast cancer: a meta-analysis
    Zhou, Yu
    Shao, Nan
    Aierken, Nijiati
    Xie, Chuanbo
    Ye, Runyi
    Qian, Xueke
    Hu, Ziye
    Zhang, Jin
    Lin, Ying
    JOURNAL OF CANCER, 2017, 8 (19): : 4098 - 4105